Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04704271 · ClinicalTrials.gov registry record · Phase 1

Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study II

A Phase 1 study of Cannabis, sponsored by Yale University.

Recruiting
Registry status
Phase 1
Development phase
100
Enrollment target
1
Study location

NCT04704271 is a Phase 1 study of Cannabis that is actively recruiting participants, run by Yale University. The registered enrollment target is 100 participants, roughly in line with the 107-participant average among 24 other Cannabis trials with a reported enrollment target. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04704271, a Phase 1 study of Cannabis, is actively recruiting participants, sponsored by Yale University.

RECRUITING
Registry status
Phase 1
Development phase
100 participants
Enrollment target
1
Study location

Study Summary

The purpose of the study is to characterize the acute effects of cannabinoids in women relative to men and to begin probing the mechanisms that may underlie gender differences.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Inhaled THC

Study Locations (1)

Connecticut

  • Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine - West Haven

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2019-10-09
Est. Completion 2025-12-01
Phase Phase 1

Sponsor

Yale University

1,492 total trials

What the Registry Record Tells You About NCT04704271

The ClinicalTrials.gov registry entry for NCT04704271 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 107-participant average among 24 other Cannabis trials with a reported enrollment target. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cannabis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT04704271 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.

Frequently Asked Questions

What is clinical trial NCT04704271 about?

NCT04704271 is a clinical study titled "Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study II". The purpose of the study is to characterize the acute effects of cannabinoids in women relative to men and to begin probing the mechanisms that may underlie gender differences.

What is the current status of trial NCT04704271?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2019-10-09. Estimated completion is 2025-12-01.

What conditions does trial NCT04704271 study?

This clinical trial studies the following conditions: Cannabis.

What interventions are being tested in trial NCT04704271?

The interventions under investigation include: Placebo (DRUG), Inhaled THC (DRUG).

Who is sponsoring clinical trial NCT04704271?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04704271 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cannabis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.